Physician profile
Cameron Delforge
NPI 1720600448
$3,054.06
in general payments reported to CMS, 2019-2025
31 companies · $831 in 2025
The $831 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $826 · 2024: $1,204 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $675.28 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $382.83 | 2023-2025 | |
| Lilly USA, LLC | $274.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $273.74 | 2022-2025 | Airsupra, Farxiga |
| Pfizer INC. | $191.72 | 2022-2025 | |
| Amgen INC. | $184.50 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $129.25 | 2023-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $91.32 | 2022-2024 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $90.47 | 2023-2025 | Trintellix |
| Tris Pharma INC | $85.44 | 2023-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $82.36 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $78.37 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $54.41 | 2024-2025 | Veozah |
| Viiv Healthcare Company | $49.45 | 2023-2025 | Apretude |
| Vivus LLC | $48.27 | 2024 | Qsymia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $38.89 | 2023 | Jornay Pm |
| Ibsa Pharma INC. | $36.61 | 2023 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $33.06 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.88 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $29.08 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $23.13 | 2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $19.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.34 | 2023 | |
| Merck Sharp & Dohme LLC | $18.06 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Dexcom, INC. | $17.78 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.73 | 2024 | Gemtesa |
| Noven Therapeutics, LLC | $17.05 | 2023 | Xelstrym |
| Gilead Sciences, INC. | $16.83 | 2023 | |
| Currax Pharmaceuticals LLC | $16.37 | 2023 | Contrave, Onzetra Xsail |
| Axsome Therapeutics, INC. | $15.09 | 2025 | Symbravo |
| Eisai INC. | $14.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Delforge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.